# the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

> **NCT05527704** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Medical University of Warsaw** · enrollment: 608 (estimated)

## Conditions studied

- TTN
- Respiratory Failure
- PPHN

## Interventions

- **DRUG:** Salbutamol
- **DRUG:** 0,9% Chloride Sodium

## Key facts

- **NCT ID:** NCT05527704
- **Lead sponsor:** Medical University of Warsaw
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-31
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 608 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527704, "the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05527704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*